Corcept Fails to Escape Antitrust Claims in Drug Kickback Case

Corcept Therapeutics Inc. must face antitrust claims alleging it blocked rival Teva Pharmaceutical Industries Ltd. from competing for a drug used to treat a rare hormonal disorder and that it paid kickbacks to physicians to keep control over the market.

Teva plausibly alleged that Corcept entered into an exclusive agreement that foreclosed competition for its brand-name drug Korlym, Judge Noël Wise of the US District Court for the Northern District of California said in a Sept. 12 order.

California-based Corcept must now contend with the potential of treble damages and exclusive-dealing claims alleging it stifled competition for less expensive ...